Nepro Carb Steady - 8 oz cans
Case of 24
Features
Ross Nepro Carb Steady - 8 oz cans
- Complete, balanced nutrition for those on dialysis
- Contains fructooligosaccharides (FOS)
- For people with chronic or acute renal failure
- Lactose and gluten free
Product Overview
Ross Nepro Carb Steady - 8 oz cans
Nepro Carb Steady
| Usage of Nepro Carb Steady: |
| Nepro Carb Steady is a moderate-protein, nutritionally complete formula with a vitamin-mineral profile specifically designed for people with chronic or acute renal failure requiring dialysis. |
| Features of Nepro Carb Steady: | |||||||||||||||||||
† 1 g water = 1 mL water = 1 cc water. |
| Availability: | |
|
Ready-To-Use
8-fl-oz cans, 24/case |
| Administration: |
|
Use under medical supervision. Not for parenteral use. Nutrient-dense products have a higher viscosity than standard 1.0 to 1.5 Cal/mL formulas. When tube feeding NEPRO by gravity drip, a 10 F or larger tube is recommended; 8 F for pump feeding. |
| Ingredients: | |
|
NEPRO Vanilla:
|
| Protein: | |||||||||||||
|
The protein content of NEPRO is adequate to replace protein
and amino acids lost during dialysis and prevent catabolism
of tissue proteins. The high-quality protein of NEPRO meets
or surpasses the standard amino acid profile for protein of
high biological value. NEPRO is gluten-free.
NEPRO Protein Source
|
| NEPRO Fat: | |||||||||||||||||||||
|
The fat blend in NEPRO is high-oleic safflower oil, canola
oil, and lecithin. This combination meets American Heart
Association recommendations1 of < 10% of
calories from both saturated and polyunsaturated fatty
acids. Fat levels in NEPRO, although somewhat higher than
suggested for healthy persons,1 are within the
range suggested for renal patients2 to achieve
the high nutrient density needed to accommodate fluid
restrictions.
NEPRO Fat Source
|
| NEPRO Carbohydrate: | |||||||||||
|
NEPRO contains corn syrup, sucrose, and
fructooligosaccharides as the carbohydrate sources. Because
renal patients may have hypertriglyceridemia and/or
aversions to sweet tastes, simple sugars have been
minimized. NEPRO is lactose-free.
NEPRO Carbohydrate Source
|
| NEPRO Fiber: | |
| NEPRO Vitamins and Minerals: | |
| NEPRO provides nutrients at levels that meet either the RDI or Estimated Safe and Adequate Daily Dietary Intake,3 or recommended intakes for dialyzed renal patients2 for 18 key vitamins and minerals in 1900 Cal (947 mL, four 8-fl-oz servings). Compared to traditional medical nutritional formulations, levels of calcium, folic acid, and pyridoxine (vitamin B6) are supplemented to meet the increased requirements of dialysis patients. Vitamin A, vitamin D, vitamin C, phosphorus, sodium, potassium, chloride, and magnesium levels are reduced in comparison to standard enteral products. Molybdenum and chromium are not added to NEPRO because blood levels of these nutrients may be elevated in renal patients. NEPRO is supplemented with the conditionally essential nutrients L-carnitine and taurine at levels within the range of typical daily intakes (261 mg/L and 160 mg/L, respectively). |
| NEPRO Osmotic Concentration: | |||||
The main determinants of the osmolality of a formula are
simple carbohydrates, electrolytes, and amino acids or
small peptides. Calorically dense (> 1.0 Cal/mL)
formulas have, as a result, a higher osmotic concentration.
* Measured on undiluted product using vapor pressure methodology. |
| Renal Solute Load: | |||||||||||||||||||
|
Renal solute load represents the solutes excreted per
liter of product consumed. The major determinants of
renal solute load are dietary protein and electrolytes.
Each milliequivalent of sodium, potassium, and chloride
contributes approximately 1 mosm to the renal solute
load; in adults, each gram of protein contributes
approximately 5.7 mosm. The electrolyte content of NEPRO
is low to facilitate individualization of intake based on
residual renal function, underlying disease(s), and other
sources of electrolytes. Because of the number of
clinical factors that influence electrolyte requirements,
nutritional care must be individualized and electrolyte
intake adjusted as necessary.
|
| Analysis: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Nutrient Facts
Carbohydrate
includes 3.7 g/8 fl oz
(15.6 g/L) as FOS.
Includes 750 IU/8 fl oz (3518 IU/L)
of
vitamin A activity from 0.57 mg/8 fl oz (2.7 mg/L)
beta-carotene.
Fatty acids equal approximately 95%
of
total fat.
In parentheses, carbon atoms/double bonds. |
| References: |
|
Clinical Research Seventy-nine patients were
fed one
of three products as a sole source of nutrition for 2 weeks
following a 1-week baseline period (used to collect
normative biochemical and gastrointestinal function
data).4 The treatment arms were a standard 2.0
Cal/mL enteral formula (STD; n = 27), NEPRO without FOS or
beta-carotene (N-; n = 26), and NEPRO with FOS and
beta-carotene (N+; n = 26). This study was designed to
evaluate the safety and tolerance of reformulated NEPRO as
a sole source of nutrition in chronic hemodialysis patients
using a prospective, randomized, single-blinded, parallel
design at three sites. After 7 days, the randomly assigned
diet was consumed as a sole source of nutrition for 14
days. Fasting routine blood chemistries were obtained
initially and at the beginning and end of the baseline and
sole-source periods (Day 1, Day 8, and Day 22). Patients
recorded consumption of product and any GI symptoms
daily. The mean (± SEM) intakes for the STD, N-, and N+ groups were, respectively, 35.47 ± 1.22, 33.43 ± 1.67, and 34.87 ± 1.91 Cal/kg/day. There was no difference in the frequency or severity of GI symptoms in patients fed the FOS-containing formula compared to FOS-free formulas. There were no changes in GI symptoms with initiation of enteral feeding compared to the frequency and severity of symptoms on renal diets. The low-phosphorus/high-calcium formulations, in contrast to the high-phosphorus standard medical nutritional formulation, decreased serum phosphorus (P = 0.02) and calcium-phosphorus product (P = 0.02) without causing hypercalcemia. Thus, NEPRO was found to be safe and well tolerated, and its nutrient profile offered advantages over standard formulations for the dietary management of ESRD patients. Specifically, low-phosphorus/high-calcium formulations resulted in lower serum phosphorus levels and decreases in the serum calcium-phosphorus product without altering the risk of hypercalcemia. This finding is significant because the products, when used as sole sources of nutrition, essentially eliminated the need for phosphate binders and calcium supplements in the population. The remaining routine blood chemistries remained constant throughout the study. NEPRO Clinical Documentation Ross Study BE51, October 1992: Use of NEPRO as a sole source of nutrition in hemodialyzed renal patients. Data available on request, Medical Nutrition Product Research and Development Department, Ross Products Division, Columbus, Ohio. References
1. Dietary guidelines for healthy American adults: A
statement for physicians and health professionals by the
Nutrition Committee, American Heart Association.
Circulation 1986;74:1465A-1468A.
2. Kopple JD: Nutrition, diet and the kidney, in Shils ME, Young VR (eds): Modern Nutrition in Health and Disease, ed 7. Philadelphia: Lea & Febiger, 1988, pp 1230-1268. 3. National Research Council: Recommended Dietary Allowances, ed 10. Washington, DC: National Academy Press, 1989. 4. Cockram DB, Hensley MK, Rodriguez M, et al: Safety and tolerance of medical nutritional products as sole sources of nutrition in people on hemodialysis. J Ren Nutr 1998;8(1):25-33. |
Part Number(s): 54106, 59666, 59660
